QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 发表日期：2022     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial 期刊论文 ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 18 作者:  Li, Ning;  Zhu, Jianqing;  Yin, Rutie;  Wang, Jing;  Pan, Lingya 收藏  |  浏览/下载：24/0  |  提交时间：2022/12/23 Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2022, 卷号: 17 作者:  Wu, Y. -L.;  Zhou, Q.;  Chen, M.;  Pan, Y.;  Jian, O. 收藏  |  浏览/下载：25/0  |  提交时间：2022/12/23 CCRT  sCRT  PD-L1 inhibitor   Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial 期刊论文 ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022 作者:  Liu, Jihong;  Yin, Rutie;  Wu, Lingying;  Zhu, Jianqing;  Lou, Ge 收藏  |  浏览/下载：33/0  |  提交时间：2022/05/05 BRCA mutation  China  olaparib  ovarian cancer  PARP inhibitor   Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial 期刊论文 LANCET ONCOLOGY, 2022, 卷号: 23 作者:  Zhou, Qing;  Chen, Ming;  Jiang, Ou;  Pan, Yi;  Hu, Desheng 收藏  |  浏览/下载：110/0  |  提交时间：2022/03/21